Study: New ABCB4 mutations tied to different ages of PFIC3 onset
Two cases of progressive familial intrahepatic cholestasis type 3 (PFIC3) with markedly different ages of disease onset due to new mutations in the ABCB4…
Two cases of progressive familial intrahepatic cholestasis type 3 (PFIC3) with markedly different ages of disease onset due to new mutations in the ABCB4…
Almost every child and adolescent who met diagnostic criteria for forms of nonalcoholic fatty liver disease under their previous names — NAFL, NASH, or…
Off-label treatment with Mirum Pharmaceuticals’ maralixibat led to clinically meaningful reductions in severe itching, or pruritus, in five children with biliary atresia, including…
The U.S. Food and Drug Administration (FDA) has turned down a request by Intercept Pharmaceuticals for the full approval of Ocaliva (obeticholic acid) as…
Women who conceive with the help of in vitro fertilization (IVF) — a commonly used assisted reproductive technology — are almost three times more likely…
Signs of improved liver health are evident in biomarker and liver scarring assessments of people with metabolic-associated steatohepatitis or MASH — a severe form of…
A study showed that a genetic mutation associated with metabolic dysfunction-associated steatotic liver disease (MASLD), a form of fatty liver disease, results in an…
Two weeks of oral methylprednisolone twice a day as an add-therapy significantly lowered signs of liver damage and inflammation among infants with cholestasis, a…
A blood-based biomarker of body-wide inflammation called a low systemic immune-inflammation index (SII) before a standard Kasai surgical procedure can accurately predict post-surgery liver…
Six months of Calliditas Therapeutics‘ investigational therapy setanaxib safely and significantly reduced signs of liver damage in people with hard-to-treat primary biliary cholangitis…